Pirtobrutinib
≥99%
- Product Code: 227946
CAS:
2101700-15-4
| Molecular Weight: | 479.43 g./mol | Molecular Formula: | C₂₂H₂₁F₄N₅O₃ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
Pirtobrutinib is used in the treatment of certain blood cancers, particularly mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). It functions as a highly selective inhibitor of Bruton's tyrosine kinase (BTK), a protein involved in B-cell receptor signaling that promotes the survival and spread of cancerous B-cells. Unlike earlier BTK inhibitors, pirtobrutinib is designed to be effective even in patients who have developed resistance mutations, such as the C481S mutation in BTK. This makes it a valuable option for patients who have relapsed or become refractory to prior BTK inhibitor therapies. It is taken orally and has shown promising response rates in clinical trials, offering a well-tolerated treatment alternative with manageable side effects. Its selectivity reduces off-target effects, contributing to a favorable safety profile.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 5mg | 10-20 days | $85.24 |
+
-
|
| 25mg | 10-20 days | $334.07 |
+
-
|
| 100mg | 10-20 days | $1,061.18 |
+
-
|
Pirtobrutinib
Pirtobrutinib is used in the treatment of certain blood cancers, particularly mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). It functions as a highly selective inhibitor of Bruton's tyrosine kinase (BTK), a protein involved in B-cell receptor signaling that promotes the survival and spread of cancerous B-cells. Unlike earlier BTK inhibitors, pirtobrutinib is designed to be effective even in patients who have developed resistance mutations, such as the C481S mutation in BTK. This makes it a valuable option for patients who have relapsed or become refractory to prior BTK inhibitor therapies. It is taken orally and has shown promising response rates in clinical trials, offering a well-tolerated treatment alternative with manageable side effects. Its selectivity reduces off-target effects, contributing to a favorable safety profile.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
$0.00
$0.00
Total :